Radiology:MRI放射组学机器学习与ADC值在评价前列腺病变的价值

2019-03-06 shaosai MedSci原创

本研究旨在比较术前MRI阅片中比较双参数非对比放射组学机器学习(RML)平均表观扩散系数和放射科医生评价前列腺病变特点的差异。

本研究旨在比较术前MRI阅片中比较双参数非对比放射组学机器学习(RML)平均表观扩散系数和放射科医生评价前列腺病变特点的差异。

本研究共纳入了316例有MRI-经直肠US融合活检指征的男性患者(训练组183例,验证组133例)。前瞻性临床读片检出的病变进行平均ADC和放射组学分析。在训练组建立整体和前列腺分区特异性随机森林RML和平均ADC模型来对临床典型前列腺癌(Gleason分级≥2)进行分类。

结果为,在测试组,放射科医生报告中前列腺病变的敏感性、特异性分别为88% (53 of 60) and specificity of 50% (79 of 159),平均ADC(最佳截断值732 mm2/sec)定量评价能够将假阳性病变80处显着减少到60(特异性为62% [99 of 159]),将假阴性从7处减到6处(敏感性90% [54 of 60])(P = .048)。放射科医生诊断报告对每位患者的敏感性和特异性分别为89% (40 of 45) 、43% (38 of 88)。平均ADC值定量评价能将FP病变由50处减少到43处(特异性为51% [45 of 88]),将FN病变由5处减少到3处(敏感性为93% [42 of 45])(P = .496)。比较评价ADC值和RML的ROC曲线下面积表明两组无差异性。

本研究表明,与临床评价相比,平均表观扩散系数(ADC)定量评价能够提高前列腺良恶性病变的能力。放射组学机器学习具有不优于评价ADC值的诊断价值。

原始出处:

Bonekamp D, Kohl S, Wiesenfarth M,et al.Radiomic Machine Learning for Characterization of Prostate Lesions with MRI: Comparison to ADC Values.Radiology.DOI:10.1148/radiol.2018173064

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1444513, encodeId=f0f41444513f0, content=<a href='/topic/show?id=3d9291459d1' target=_blank style='color:#2F92EE;'>#评价#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91459, encryptionId=3d9291459d1, topicName=评价)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Fri Mar 08 14:37:00 CST 2019, time=2019-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1575013, encodeId=b4a115e5013fe, content=<a href='/topic/show?id=62141962b0' target=_blank style='color:#2F92EE;'>#ADC值#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1962, encryptionId=62141962b0, topicName=ADC值)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4dd16047351, createdName=周虎, createdTime=Fri Mar 08 14:37:00 CST 2019, time=2019-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1583172, encodeId=aaba15831e203, content=<a href='/topic/show?id=f6e1611840d' target=_blank style='color:#2F92EE;'>#机器#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61184, encryptionId=f6e1611840d, topicName=机器)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=13dc16973127, createdName=ms6279672939590805, createdTime=Fri Mar 08 14:37:00 CST 2019, time=2019-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=362217, encodeId=c04936221e98, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Thu Mar 07 22:14:31 CST 2019, time=2019-03-07, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1444513, encodeId=f0f41444513f0, content=<a href='/topic/show?id=3d9291459d1' target=_blank style='color:#2F92EE;'>#评价#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91459, encryptionId=3d9291459d1, topicName=评价)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Fri Mar 08 14:37:00 CST 2019, time=2019-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1575013, encodeId=b4a115e5013fe, content=<a href='/topic/show?id=62141962b0' target=_blank style='color:#2F92EE;'>#ADC值#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1962, encryptionId=62141962b0, topicName=ADC值)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4dd16047351, createdName=周虎, createdTime=Fri Mar 08 14:37:00 CST 2019, time=2019-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1583172, encodeId=aaba15831e203, content=<a href='/topic/show?id=f6e1611840d' target=_blank style='color:#2F92EE;'>#机器#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61184, encryptionId=f6e1611840d, topicName=机器)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=13dc16973127, createdName=ms6279672939590805, createdTime=Fri Mar 08 14:37:00 CST 2019, time=2019-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=362217, encodeId=c04936221e98, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Thu Mar 07 22:14:31 CST 2019, time=2019-03-07, status=1, ipAttribution=)]
    2019-03-08 周虎
  3. [GetPortalCommentsPageByObjectIdResponse(id=1444513, encodeId=f0f41444513f0, content=<a href='/topic/show?id=3d9291459d1' target=_blank style='color:#2F92EE;'>#评价#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91459, encryptionId=3d9291459d1, topicName=评价)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Fri Mar 08 14:37:00 CST 2019, time=2019-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1575013, encodeId=b4a115e5013fe, content=<a href='/topic/show?id=62141962b0' target=_blank style='color:#2F92EE;'>#ADC值#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1962, encryptionId=62141962b0, topicName=ADC值)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4dd16047351, createdName=周虎, createdTime=Fri Mar 08 14:37:00 CST 2019, time=2019-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1583172, encodeId=aaba15831e203, content=<a href='/topic/show?id=f6e1611840d' target=_blank style='color:#2F92EE;'>#机器#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61184, encryptionId=f6e1611840d, topicName=机器)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=13dc16973127, createdName=ms6279672939590805, createdTime=Fri Mar 08 14:37:00 CST 2019, time=2019-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=362217, encodeId=c04936221e98, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Thu Mar 07 22:14:31 CST 2019, time=2019-03-07, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1444513, encodeId=f0f41444513f0, content=<a href='/topic/show?id=3d9291459d1' target=_blank style='color:#2F92EE;'>#评价#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91459, encryptionId=3d9291459d1, topicName=评价)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Fri Mar 08 14:37:00 CST 2019, time=2019-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1575013, encodeId=b4a115e5013fe, content=<a href='/topic/show?id=62141962b0' target=_blank style='color:#2F92EE;'>#ADC值#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1962, encryptionId=62141962b0, topicName=ADC值)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4dd16047351, createdName=周虎, createdTime=Fri Mar 08 14:37:00 CST 2019, time=2019-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1583172, encodeId=aaba15831e203, content=<a href='/topic/show?id=f6e1611840d' target=_blank style='color:#2F92EE;'>#机器#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61184, encryptionId=f6e1611840d, topicName=机器)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=13dc16973127, createdName=ms6279672939590805, createdTime=Fri Mar 08 14:37:00 CST 2019, time=2019-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=362217, encodeId=c04936221e98, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Thu Mar 07 22:14:31 CST 2019, time=2019-03-07, status=1, ipAttribution=)]
    2019-03-07 1209e435m98(暂无昵称)

    学习了,谢谢分享

    0

相关资讯

Radiology:扩散峰度成像放射组学能不能排除乳腺癌的可疑性?

本研究旨在评估乳腺组织成像数据系统(Bi-RADS)4类和5类乳腺组织病变的放射组学模型,这些病变是利用与活检相似的敏感阈值从乳腺组织优化峰度磁共振(MR)成像的病变特征提取得到的。

Radiology:CT放射组学分析中有哪些特征才是有用的呢?

本研究旨在鉴定CT中重复性和必要性的放射组学特征(RFs),并将结果发表在Radiology上。

笔记收藏:影像组学/放射组学

这仍然是一篇学习笔记。近期在不同的学术会议上,有幸聆听学习了几位影像组学的大咖做报告,受益匪浅。以大咖们的报告为指导,自己也学习查找了一些文献,加入了一点点自己的理解和想法,整理成一篇笔记,与大家分享。 名词解释:影像组学(Radiomics) “影像组学”,一共4个字,每个字都是常见字啊。但4个字放一起啥意思?好吧,我们把它们拆成“影像”和“组学”两个词来说。这里的“影像”通常指的就是放

Radiology:靶向药物和放射组学在乳腺癌诊断和治疗中的价值

靶向药物是针对个体的基因型和表型特征进行优化的药物。

Radiology:胶质母细胞瘤MRI放射组学亚型对预测生存期的价值

本研究旨在探究MRI放射组学征象联合临床和基因指标在提高多形性胶质母细胞瘤(GBM)生存期的价值。

Eur Radiol:基于T2加权脂肪抑制和扩散加权 MRI的放射学分析在术前预测乳腺癌前哨淋巴结转移的价值

前哨淋巴结是原发肿瘤引流区域淋巴结中的特殊淋巴结,是原发肿瘤发生淋巴结转移所必经的第一批淋巴结。前哨淋巴结作为阻止肿瘤细胞从淋巴道扩散的屏障,其临床意义已受到人们的重视。本研究旨在预测基于T2加权脂肪抑制(T 2-FS)和扩散加权 MRI(DWI)的放射学分析在术前预测乳腺癌前哨淋巴结(SLN)转移的价值,并将结果发表在Eur Radiol上。